anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In France, 25% of perpetrators of sexual offenses are minors. Faced with this increasingly present problem in our society, the answer seems to be more on the side of education and care. However, this new problem confronts us with the limits of our care and forces us to reconsider the organization of care. Indeed, to date, there is no specific support for juvenile sex offenders. Little research exists on the subject because of the many difficulties in setting up this type of study: low power, problem of definition, variables that are difficult to compare, few therapists specialized in this field... In fact, studies must continue to demonstrate the effectiveness of psychoeducational treatment. Although there is no consensus on the profiles of juvenile sex offenders in the literature, there are common characteristics among these individuals. Indeed, the lack of social skills, relationship difficulties, empathy, self-esteem, sex education, impulse control and therefore self-control are issues that can be worked on by psychoeducation.

CRIAVS-LR's team have therefore decided to create a specific psychoeducation group for minors and young adults who are perpetrators of sexual violence. The objective is to improve their skills of knowing, knowing how to be and knowing how to do in the areas of affective and sexual interpersonal relationships and thus find alternative solutions to violence, particularly sexual violence. The qualitative aspect of this study would make it possible to provide data in this still little explored field, to try to understand the experience of the young people participating in this group and to improve its structure and content so that it reaches best its goals.
The invention discloses a pulse sustained-release oral preparation and a preparation method thereof. The pulse sustained-release oral preparation includes a sustained-release tablet core and a time-lag coating layer. The sustained-release tablet core comprises a sustained-release drug pellet and tablet core auxiliary materials. The sustained-release drug pellet includes: 50-80% of a blank pill core; 2-10% of an expansion layer; 3-20% of a main drug layer; and 10-30% of a sustained-release coating layer. The preparation method comprises the steps of: (1) under stirring, adding the expansion layer, the main drug layer and the sustained-release coating layer into a benign solvent including water and/or alcohol of C1-C4 respectively, then wrapping the blank pill core with the layers, and collecting the formed sustained-release drug pellet; (2) mixing the sustained-release drug pellet with the tablet core auxiliary materials, and conducting direct compression to obtain the sustained-release tablet core; and (3) wrapping the sustained-release tablet core with the time-lag coating layer, thus obtaining the pulse sustained-release oral preparation. The pulse sustained-release oral preparation provided by the invention can realize rapid release and slow release of drugs by the same pellet, and has the advantages of stable absorption, high security, small individual difference, and small toxic and side effect.
BCNU: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease 2019 (COVID-19) have a poor prognosis, as noted in several case reports of recipients who had COVID-19 before the infusion. We report the case of a 70-year-old woman who developed COVID-19 immediately before CAR-T therapy for high-grade B-cell lymphoma. She received Tixagevimab-Cilgavimab chemotherapy and radiation therapy but never achieved remission. She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term molnupiravir. On day 28 post-infection, lymphodepleting chemotherapy was restarted after a negative polymerase chain reaction (PCR) test was confirmed. The patient did not experience recurrence of COVID-19 symptoms or severe cytokine release syndrome. Based on the analysis and comparison of the previous reports with this case, we believe that CAR-T therapy should be postponed until a negative PCR test is confirmed. In addition, Tixagevimab-Cilgavimab and long term direct-acting antiviral agent treatment can be effective prophylaxis for severe COVID-19 and shortening the duration of infection.
Fathers allocated to the Working Out Dads (WOD) arm will receive the intervention program. WOD is a 6-week manualised program. The weekly 90 minute sessions combine a one hour facilitated discussion by a male facilitator trained in delivery of WOD and a 30-minute gym workout provided by a personal trainer. The group size ranges from 6-10 fathers, with 14 groups running over the study period. The weekly sessions are provided in the evenings, in local gyms or a community setting (e.g., maternal child health centre, local council rooms, local hall, local park, Tweddle Child \& Family Health Service).
Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
OBJECTIVE: To examine the value of including an open label phase after a clinical trial of pain treatments by examining participant characteristics and potential benefits.
METHOD: Secondary data analysis. Veterans with chronic pain who completed a randomized controlled trial (RCT) comparing hypnosis, mindfulness meditation, and pain education were invited to participate in an open label phase. Average and worst pain intensities, pain interference, and depression were assessed pre- and postopen label phase; global impressions of change and treatment satisfaction were assessed at postopen label phase only.
RESULTS: Of those who were offered the open label phase, 40% (n = 68) enrolled. Enrollees were likely to be older, to have attended more sessions in the RCT, to be satisfied with their first treatment, and to perceive improvement in their ability to manage pain after the RCT. In the open label phase, depression and worst pain decreased across all three treatment conditions. No other improvements were observed. However, most Veterans perceived improvements in pain intensity, ability to manage pain, and pain interference, and were satisfied with the second intervention.
CONCLUSIONS: There appears to be some value to adding an open label phase to the end of a trial of pain treatments. A substantial portion of study participants elected to participate and reported it to be beneficial. Exploring data from an open label phase can illuminate important aspects of patient experience, barriers to and facilitators of care, as well as treatment preferences. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Dofetilide shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, I Kr. At concentrations covering several orders of magnitude, dofetilide blocks only I Krwith no relevant block of the other repolarizing potassium currents (e.g., I Ks, I K1). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors. 

Electrophysiology

Dofetilide increases the monophasic action potential duration in a predictable, concentration- dependent manner, primarily due to delayed repolarization. This effect, and the related increase in effective refractory period, is observed in the atria and ventricles in both resting and paced electrophysiology studies. The increase in QT interval observed on the surface ECG is a result of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles.

Dofetilide did not influence cardiac conduction velocity and sinus node function in a variety of studies in patients with or without structural heart disease. This is consistent with a lack of effect of dofetilide on the PR interval and QRS width in patients with pre-existing heart block and/or sick sinus syndrome.

In patients, dofetilide terminates induced re-entrant tachyarrhythmias (e.g., atrial fibrillation/flutter and ventricular tachycardia) and prevents their re-induction. Dofetilide does not increase the electrical energy required to convert electrically induced ventricular fibrillation, and it significantly reduces the defibrillation threshold in patients with ventricular tachycardia and ventricular fibrillation undergoing implantation of a cardioverter-defibrillator device.

Hemodynamic Effects

In hemodynamic studies, dofetilide had no effect on cardiac output, cardiac index, stroke volume index, or systemic vascular resistance in patients with ventricular tachycardia, mild to moderate congestive heart failure or angina, and either normal or low left ventricular ejection fraction. There was no evidence of a negative inotropic effect related to dofetilide therapy in patients with atrial fibrillation. There was no increase in heart failure in patients with significant left ventricular dysfunction (see CLINICAL STUDIES, Safety in Patients with Structural Heart Disease, DIAMOND Studies). In the overall clinical program, dofetilide did not affect blood pressure. Heart rate was decreased by 4–6 bpm in studies in patients
PROBLEM TO BE SOLVED: To obtain a cancer metastasis-suppressing agent capable of effectively suppressing cancer metastasis by including an analgesic for alleviating cancer pain therein. SOLUTION: This cancer metastasis-suppressing agent comprises an analgesic for alleviating cancer pain as an active ingredient. It is preferable that the cancer pain is a cancer pain in middle stage or last stage of cancer. The analgesic is an anesthetic analgesic which is morphine, opium, ethylmorphine, oxycodone, etc. The suppressing agent is preferably used for suppressing cancer metastasis except when surgical operation is carried out. The daily dose of the suppressing agent is preferably 0.01 mg to 2 g/adult. The suppressing agent can be administered in combination with a carrier or a diluent or a medicinal additive. Water, physiological saline, etc., is exemplified as a carrier, etc., suitable for parenteral administration and lactose, etc., is exemplified as a carrier or an additive suitable for oral administration.
Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
A radiopaque composition is provided that includes an inorganic opacifying agent distributed through an aqueous gelatinous substance in an aqueous solvent. A process for making a radiodense vascular fill composition includes adding a gelatinous substance to an aqueous solution. An inorganic opacifying agent suspension is formed in a saline solution or water. The inorganic opacifying agent and gelatin are mixed with water or saline. A process of imaging a vascular system of a subject includes placing a subject under anesthesia or sedation and exsanguinating the subject. An isotonic fluid is then flushed through the vascular system and the radiopaque composition is infused into the subject circulatory system at a temperature of 40 degrees Celsius or greater. After waiting a given time interval for the radiopaque composition to cool and form a solid gel, an imaging scan is performed on the subject.
Substances for restraining the growth of tumours are obtained from animal organs, body liquids, or bacteria, by intimate trituration with water-soluble physiologically innocuous solid substances which have no albumen-precipitating effect, followed by extraction with water and if desired evaporation of the extract to dryness.  Animal organs specified are liver, spleen, placenta and thymus; blood and bacillus pyocyaneus are also mentioned. The animal materials may be taken from animals immunized against malignant tumours.  Solids employed are sugars such as grape, cane, and milk sugar, arabinose, mannitol and sorbite, ureas, acid amides, and citric or other organic acids and their salts. Disinfectants such as salicylic or benzoic acids may also be added.  It is stated that plasmolysis of the cells takes place and facilitates the extraction.  Albumen and ballast substances may be removed from the extracts as by precipitation with gaseous or solid carbonic acid, or by adsorption on animal charcoal, aluminium hydroxide, kaolin, or fuller's earth.  Known processes wherein tissue is treated with inorganic salts such as calcium sulphate, copper sulphate, sodium sulphate and sodium chloride or wherein comminuted organs are extracted with water, Ringer's solution, acetone or alcohol, or wherein autolysates or pressed juices are employed, are also referred to.
PURPOSE:To provide the titled composition containing sulfonamide and chitosan or its salt. CONSTITUTION:An antibacterial composition can be prepared by combining a sulfonamide (e.g. sulfamethoxazole) with chitosan [a substance obtained by deacetylating chitin (polysaccharide of N-acetyl-D-glucosamine) existing in the crust of crab, shrimp, etc. in an alkaline aqueous solution (e.g. NaOH solution)]. The ratio of both components is arbitrarily selected according to the use. An excellent synergistic effect can be attained by the combination of both components.
This study will be a longitudinal randomized two-arm parallel group clinical trial. Participants will be randomized 1:1 to either PST-Concussion or treatment as usual (TAU). Participants assigned to PST-Concussion will receive six, approximately 30-minute telehealth treatment sessions. Assessments will include standard self-report and cognitive measures that will be administered at baseline, post-treatment, and three-month follow-up. The primary objective of this study will be to evaluate the effectiveness of PST-Concussion in reducing psychological distress compared to TAU. Secondary and tertiary objectives will be to evaluate whether PST-Concussion is associated with appreciable change in subjective neurocognitive functioning, objective neurocognitive functioning, psychosocial functioning, and disability and quality of life. Multi-level modeling will be used to evaluate treatment effects at post-treatment and three-month follow-up. A test of non-inferiority will be conducted to evaluate the potential durability of observed treatment effects from post-test to follow-up. A portion of participants assigned to PST-Concussion will also be interviewed at post-treatment or follow-up to gain insight into the practical impact of intervention on psychosocial functioning and quality of life.
Participants in the DATA condition, instead of access to a generic digital assistant, will have DATA at their disposal to solve the queries and will be encouraged to use it as the primary resource. Qualitative data on how they use this tool, in isolation and in conjunction with other sources of information, will be collected. Following completion of the problems, as in Phase 2, measures of DATA usability will be collected including usefulness and comprehension associated with each tool, perceived mental workload, and usability with an efficient, two-item test based on the widely used System Usability Scale: UMUX-LITE). The investigators will then conduct an audio-recorded semi-structured exit interview about various perceptions participants had regarding the challenges associated with successfully solving the health-management problems.
Objective: To provide an updated summary of the literature on dextromethorphan quinidine for the treatment of agitation in dementia. Data Sources: PubMed, Medline, APA PsycINFO, Embase, and Cochrane Collaboration were searched from inception to January 7, 2024 using the keywords dementia, dextromethorphan, and quinidine. The search was limited to the English language and human subjects. Study Selection: Twenty-four articles underwent full-text review. One randomized controlled trial (RCT) and 2 case reports were included. Twenty one studies were excluded because they were editorials or commentaries, were not treatment studies, or were assessing outcomes other than agitation. Data Extraction: The 3 included studies underwent full-text review. A qualitative analysis of the data was performed, and abstracted data included patient diagnosis and symptoms, treatment dose and duration of dextromethorphan-quinidine, and symptom response. Data Synthesis: One RCT and 2 case reports showed an improvement in dementia-related agitation with dextromethorphan-quinidine treatment; however, the data are limited. Conclusion: Though all the identified studies demonstrated that treatment with dextromethorphan improved agitation, more evidence is needed to establish its potential efficacy and associated risks for this patient population. Future studies should include diverse types of dementia, a variety of treatment settings, and longer duration of treatment. Prim Care Companion CNS Disord 2024;26(6):24nr03737. Author affiliations are listed at the end of this article.
BACKGROUND: Rewarming therapies for accidental hypothermia (AH) include extracorporeal membrane oxygenation (ECMO) and non-ECMO related (conventional) therapies. However, there are limited data available to inform the selection of conventional rewarming therapy. The aim of the present study was to explore what patients' factors and which rewarming therapy predicted favorable prognosis.
METHODS: This study is a secondary analysis of the Intensive Care with Extra Corporeal membrane oxygenation Rewarming in Accidentally Severe Hypothermia (ICE-CRASH) study, a multicenter prospective, observational study conducted in Japan. Enrolled in the ICE-CRASH study were patients aged ≥18 years with a core temperature of ≤32 °C who were transported to the emergency departments of 36 tertiary care hospitals in Japan between 1 December 2019 and 31 March 2022, among whom those who were rewarmed with conventional rewarming therapy were included in the present study. Logistic regression analysis was performed with 28-day survival as the objective variable; and seven factors including age, activities of daily living (ADL) independence, sequential organ failure assessment (SOFA) score, and each rewarming technique as explanatory variables. We performed linear regression analysis to identify whether each rewarming technique was associated with rewarming rate.
RESULTS: Of the 499 patients enrolled in the ICE-CRASH study, 371 were eligible for this secondary analysis. The median age was 81 years, 50.9% were male, and the median initial body temperature was 28.8 °C. Age (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.94-1.00) and SOFA score (OR: 0.73, 95% CI: 0.67-0.81) were associated with lower survival, whereas ADL independence (OR: 2.31, 95% CI: 1.15-4.63) was associated with higher survival. No conventional rewarming therapy was associated with 28-day survival. Hot bath was associated with a high rewarming rate (regression coefficient: 1.14, 95% CI: 0.75-1.53).
CONCLUSION: No conventional rewarming therapy was associated with improved 28-day survival, which suggests that background factors such as age, ADL, and severity of condition contribute more to prognosis than does the selection of rewarming technique.
PURPOSE:To safely obtain the subject compound in a large amount without danger of viral infection by successively passing vitronectin-containing milk through an anion exchanger, a lectin-immobilized carrier and a glycosaminoglycan-immobilized carrier and eluting the absorbed substances. CONSTITUTION:Colostrum of a cow milk collected within one day immediately after parturition is separated as nonfat milk by centrifugal separation and acetic acid is acid is added to the nonfat milk so as to control the pH to 4.6 to solidify and precipitate casein. Then the precipitate is subjected to centrifugal separation to afford a whey fraction. An aqueous solution of ammonia is added to the acidified whey so as to adjust the pH to 6.0 and ammonium sulfate is added to the solution so as to give 35% degree of saturation and the precipitate is centrifuged to collect a supernatant. Ammonium sulfate is added to the supernatant so as to give 40% degree of saturation and the resultant precipitate containing vitronectin is recovered. The precipitate is dissolved in a buffer solution and is successively absorbed into an anion exchanger, a lectin- immobilized carrier and a glycosaminoglycan-immobilized carrier, and then eluted, thereby vitronectin in the milk is recovered.
<P>PROBLEM TO BE SOLVED: To provide an agent for prevention of graft loss and to provide a method for screening the agent.  <P>SOLUTION: The agent for prevention of graft loss comprises an NKT cell ligand such as α-galactosylceramide etc. The agent can prevent the graft loss in clinical pancreas islets transplantation or the like and therefore can contribute to the improvement in transplantation efficiency. The method for screening a compound for use in the prevention/treatment of graft loss comprises selecting a compound inhibiting the activation of an NKT cell, the production of IFN-γ of CD11b<SP>+</SP>cell or the like. By using the screening method, it becomes possible to produce an agent for preventing/treating premature graft loss by a new mechanism.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Before administering MULTITRACE® \- 5 in TPN solutions, the physician must assess the metabolic requirements for trace elements and disease state of the patient. Frequent determinations of serum levels of the various trace elements are suggested as a guideline for adjusting the dosage or completely omitting the solution. ZINC is eliminated via the intestine and kidneys. The possibility of retention should be considered in patients with malfunctioning excretory routes. COPPER and MANGANESE are eliminated via the bile, therefore the possibility of retention of these elements should be considered in patients with biliary obstruction. Ancillary routes of MANGANESE excretion, however, include pancreatic juice, or reabsorption into the lumen of duodenum, jejunum, or ileum.

In assessing the contribution of CHROMIUM supplements to maintenance of normal glucose homeostasis, consideration should be given to the possibility that the patient may be diabetic, in which case oral or intravenous antidiabetic medication may be indicated.

As SELENIUM is eliminated in urine and feces, SELENIUM supplements may be adjusted, reduced or omitted in renal dysfunction and/or gastrointestinal malfunction. In patients receiving blood transfusions, contribution from such transfusions should also be considered. Frequent selenium plasma level determinations are suggested as a guideline.

In animals, SELENIUM has been reported to enhance the action of Vitamin E and decrease the toxicity of mercury, cadmium, and arsenic.